but efficacy suffers when 1/3 patients are not on targeted dose
It's been shown that patients with favorable genetics (i.e. WT) experience efficacy at much smaller doses; therefore, patients who couldn't be up-titrated were likely those experiencing efficacy at lower doses.
All that means is there would be less patients in the higher dose arm and more in the lower. 88% reached their target; that's significant.
This is likely the reason that the AD TLD used aggregate calculations. Missling stated that there was little difference in efficacy between 30mg and 50mg. 30mg (and lower for some) is efficacious for many.
Market Data 
Markets 
AI
